Cargando…

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers

Detalles Bibliográficos
Autores principales:	Salvagno, Gian Luca, Henry, Brandon M., Pighi, Laura, De Nitto, Simone, Gianfilippi, Gian Luca, Lippi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241575/ https://www.ncbi.nlm.nih.gov/pubmed/34214516 http://dx.doi.org/10.1016/j.jinf.2021.06.024

Ejemplares similares

Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Evaluación de la prueba Fluorecare de anticuerpos contra la proteína Spike del SARS-CoV-2 en la práctica real
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Cellular immunity against SARS-CoV-2 depends on the serological status
por: Pighi, Laura, et al.
Publicado: (2023)

The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

The Comparability of Anti-SARS-CoV-2 IgG Levels Measured with Different Immunoassays Varies over Time after Primary BNT162b2 Vaccination and Homologous Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
por: Syrimi, Natalia, et al.
Publicado: (2023)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
por: Cortés-Sarabia, Karen, et al.
Publicado: (2022)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients
por: Balčiuvienė, Vilma, et al.
Publicado: (2023)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Severe hyponatraemia with cerebral oedema after Pfizer BNT162b2 mRNA vaccination against COVID-19
por: Dharma, J.F.M., et al.
Publicado: (2023)

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Lower nasopharyngeal viral load in young SARS-CoV-2-positive subjects
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_docg9un60uc4r08e7ic1vflaj3